Materials and Methods: This randomized single-blind clinical trial included 88 patients with femoral peritrochanteric fracture in Shohada Hospital of Tabriz, Iran from January 2019 to December 2019. The participants were randomly allocated into two equal groups (n=44 each) receiving enoxaparin (40 mg subcutaneously once daily for 28 days) and rivaroxaban (10 mg orally once daily for 28 days). Using independent t test in SPSS version 20, the results of clinical examinations and ultrasonography for the diagnosis of DVT at the end of intervention were compared between the two groups. A P value less than 0.05 was considered as statistically significant.

Results: No significant differences were observed in laboratory results and DVT-related symptoms between the two groups, as well as before and after the intervention (intragroup). Also, the prevalence of DVT at the end of the study was zero.

Conclusions: According to our results, there was no difference in the prevalence of DVT and short-term (one-month) complications between the two groups receiving rivaroxaban and enoxaparin after the peritrochanteric femur fracture.